|
WO2020172565A1
|
|
Methods and materials for increasing or maintaining nicotinamide mononucleotide adenylyl transferase-2 (nmnat2) polypeptide levels
|
|
WO2020163689A1
|
|
20-hete formation inhibitors
|
|
WO2020160542A1
|
|
One-step gene therapy for duchenne muscular dystrophy via gene replacement and anti-inflammation
|
|
US2020270561A1
|
|
Multi-well mechanical stimulation systems and incubators
|
|
US2020253885A1
|
|
Vaginal Films
|
|
WO2018005780A1
|
|
Artificial cells and delivery devices for use in tissue engineering, and related methods
|
|
US2017367981A1
|
|
Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
|
|
WO2017197080A1
|
|
Modulators of p97 aaa atpase activity
|
|
WO2017193000A1
|
|
Electron, radical, or reactive oxygen species-scavenging agent based therapy of inborn errors of fatty acid oxidation and oxidative phosphorylation
|
|
WO2017165449A1
|
|
Thermoresponsive hydrogel containing polymer microparticles for noninvasive ocular biologic delivery
|
|
US2017267556A1
|
|
Managing naturally occurring radioactive material in wastewater
|
|
US2017252485A1
|
|
Ovarian-derived hydrogels for biomedical and biotechnology applications
|
|
WO2017152039A1
|
|
Protection and delivery of multiple therapeutic proteins
|
|
US2017253854A1
|
|
Use of Adipose-Derived Stem Cells for Glaucoma Treatment
|
|
US2017135639A1
|
|
Skin screw electrodes
|
|
WO2017075596A1
|
|
Use of a linear b cell epitope of ns1 protein to treat dengue virus
|
|
WO2017040537A1
|
|
Compounds for bone healing
|
|
WO2017004073A1
|
|
Bisnitroxides
|
|
US2016361443A1
|
|
Ultrasound Molecular Imaging With Targeted Biocompatible Microbubbles
|
|
WO2016176410A1
|
|
Image enhancement using virtual averaging
|
